Bolt Biotherapeutics, Inc. (BOLT)
| Market Cap | 8.21M |
| Revenue (ttm) | 6.50M |
| Net Income (ttm) | -29.58M |
| Shares Out | 1.92M |
| EPS (ttm) | -16.34 |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 12,146 |
| Open | 4.180 |
| Previous Close | 4.200 |
| Day's Range | 4.010 - 4.400 |
| 52-Week Range | 3.750 - 7.200 |
| Beta | 1.13 |
| Analysts | Buy |
| Price Target | 41.00 (+859.04%) |
| Earnings Date | Aug 13, 2026 |
About BOLT
Bolt Biotherapeutics, Inc., a clinical-stage biopharmaceutical company, develops novel immunotherapies for the treatment of cancer. The company’s pipeline products include BDC-4182, a next-generation Boltbody ISAC that targets the tumor-associated antigen claudin 18.2 for the treatment of gastric/gastroesophageal junction cancer, pancreatic cancer, and other tumor types; BDC-3042, a dectin-2 agonist antibody program for the treatment of non-small cell lung cancer, melanoma, and other solid tumors; CEA ISAC, a Boltbody ISAC targeting carcinoembr... [Read more]
Financial Performance
In 2025, Bolt Biotherapeutics's revenue was $7.70 million, an increase of 0.07% compared to the previous year's $7.69 million. Losses were -$33.38 million, -47.12% less than in 2024.
Financial StatementsAnalyst Forecast
According to 4 analysts, the average rating for BOLT stock is "Buy." The 12-month stock price target is $41.0, which is an increase of 859.04% from the latest price.
News
Bolt Metals Announces Closing of Option to Acquire the High-Grade Floralia Iron Project
VANCOUVER, BC / ACCESS Newswire / June 12, 2026 / Bolt Metals Corp. ("Bolt" or the "Company") (CSE:BOLT)(OTCQB:PCRCF)(FSE:A3D8AK), is pleased to announce that, further to its press releases dated May ...
Bolt Biotherapeutics initiated with a Buy at Rodman & Renshaw
Rodman & Renshaw initiated coverage of Bolt Biotherapeutics (BOLT) with a Buy rating and $22 price target The firm cites the company’s “first-in-class” Claudin 18.2 immune-stimulating antibody conjuga...
Bolt Biotherapeutics Reports First Quarter 2026 Financial Results and Provides Business Update
REDWOOD CITY, Calif., May 12, 2026 (GLOBE NEWSWIRE) -- Bolt Biotherapeutics (Nasdaq: BOLT), a clinical-stage biopharmaceutical company developing novel immunotherapies for the treatment of cancer, tod...
Bolt Biotherapeutics Quarterly report: Q1 2026
Bolt Biotherapeutics has published its Q1 2026 quarterly earnings report on May 12, 2026.
Bolt Biotherapeutics Earnings release: Q1 2026
Bolt Biotherapeutics released its Q1 2026 earnings on May 12, 2026, summarizing the period's financial results.
Bolt Biotherapeutics Proxy statement: Proxy filing
Bolt Biotherapeutics filed a proxy statement on April 28, 2026, providing details for shareholder voting and corporate governance matters.
Bolt Biotherapeutics Proxy statement: Proxy filing
Bolt Biotherapeutics filed a proxy statement on April 28, 2026, providing details for shareholder voting and corporate governance matters.
Bolt Biotherapeutics reports Q4 EPS ($3.84), consensus ($5.52)
Reports Q4 revenue $2.5M, consensus $857,250. “BDC-4182 is the first of our next-generation Boltbody ISACs to enter the clinic, and we saw a clear difference versus our first-gen ISACs in…
Bolt Biotherapeutics Reports Fourth Quarter and Full-Year 2025 Financial Results and Provides Business Update
REDWOOD CITY, Calif., March 12, 2026 (GLOBE NEWSWIRE) -- Bolt Biotherapeutics (Nasdaq: BOLT), a clinical-stage biopharmaceutical company developing novel immunotherapies for the treatment of cancer, t...
Bolt Biotherapeutics Earnings release: Q4 2025
Bolt Biotherapeutics released its Q4 2025 earnings on March 12, 2026, summarizing the period's financial results.
Bolt Biotherapeutics Annual report: Q4 2025
Bolt Biotherapeutics has published its Q4 2025 annual report on March 12, 2026.
Bolt Biotherapeutics to Participate in Upcoming March Conferences
REDWOOD CITY, Calif., Feb. 24, 2026 (GLOBE NEWSWIRE) -- Bolt Biotherapeutics (Nasdaq: BOLT), a clinical-stage biopharmaceutical company developing novel immunotherapies for the treatment of cancer, to...
Bolt Biotherapeutics reports Q3 EPS ($3.72), consensus ($5.39)
Reports Q3 revenue $2.17M, consensus $820,800. “In the third quarter, we focused on developing BDC-4182, the first next-generation Boltbody ISAC in our pipeline. We are actively enrolling patients wit...
Bolt Biotherapeutics Reports Third Quarter 2025 Financial Results and Provides Business Update
Initial clinical data for BDC-4182 Phase 1 dose escalation study expected in 3Q 2026 Cash balance of $38.8 million as of September 30, 2025 anticipated to fund key milestones into 2027 REDWOOD CITY, ...
Bolt Biotherapeutics Earnings release: Q3 2025
Bolt Biotherapeutics released its Q3 2025 earnings on November 12, 2025, summarizing the period's financial results.
Bolt Biotherapeutics Quarterly report: Q3 2025
Bolt Biotherapeutics has published its Q3 2025 quarterly earnings report on November 12, 2025.
Bolt Biotherapeutics assumed with a Buy at H.C. Wainwright
H.C. Wainwright assumed coverage of Bolt Biotherapeutics (BOLT) with a Buy rating and $7 price target The company’s lead asset, BDC-4182, differentiates itself relative to antibody-drug conjugates sin...
Bolt Biotherapeutics to reduce workforce by 50%, gives update on BDC-4182 study
Bolt Biotherapeutics (BOLT) announced an update on the ongoing Phase 1 dose escalation study of BDC-4182, a Boltbody ISAC clinical candidate targeting claudin 18.2, a clinically validated target in on...
Bolt Biotherapeutics Provides Update on BDC-4182 and Extends Cash Runway into 2027
REDWOOD CITY, Calif., Oct. 01, 2025 (GLOBE NEWSWIRE) -- Bolt Biotherapeutics (Nasdaq: BOLT), a clinical-stage biopharmaceutical company developing novel immunotherapies for the treatment of cancer, to...
Bolt Biotherapeutics target adjusted to $75 at Lake Street after reverse split
Lake Street analyst Chad Messer raised the firm’s price target on Bolt Biotherapeutics (BOLT) to $75 from $4 and keeps a Buy rating on the shares after Bolt ended Q2…
Bolt Biotherapeutics reports Q2 EPS ($4.46), consensus ($6.27)
Reports Q2 revenue $1.8M, consensus $819,750. “In the second quarter we focused on advancing BDC-4182, the first next-generation Boltbody(TM) ISAC in our pipeline,” said Willie Quinn, president and CE...
Bolt Biotherapeutics Reports Second Quarter 2025 Financial Results and Provides Business Update
REDWOOD CITY, Calif., Aug. 14, 2025 (GLOBE NEWSWIRE) -- Bolt Biotherapeutics (Nasdaq: BOLT), a clinical-stage biopharmaceutical company developing novel immunotherapies for the treatment of cancer, to...
Bolt Biotherapeutics Earnings release: Q2 2025
Bolt Biotherapeutics released its Q2 2025 earnings on August 14, 2025, summarizing the period's financial results.
Bolt Biotherapeutics Quarterly report: Q2 2025
Bolt Biotherapeutics has published its Q2 2025 quarterly earnings report on August 14, 2025.
Bolt Biotherapeutics Inc trading halted, news pending
19:50 EDT Bolt Biotherapeutics (BOLT) Inc trading halted, news pending